Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.56 |
| ▸ | HPSE | Q9Y251 | 7/20 | 0.53 |
| ▸ | FGF2 | P09038 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | IGF2R | P11717 | 4/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13857778 | 1.00 | AKT1 (0.56) | AKT1HPSEFGF2GBA1MAPK1 | |
| SCHEMBL20531001 | 1.00 | AKT1 (0.56) | AKT1HPSEFGF2GBA1MAPK1 | |
| SCHEMBL18953026 | 1.00 | AKT1 (0.56) | AKT1HPSEFGF2GBA1MAPK1 | |
| SCHEMBL21628176 | 1.00 | AKT1 (0.56) | AKT1HPSEFGF2GBA1MAPK1 | |
| SCHEMBL21628175 | 1.00 | AKT1 (0.56) | AKT1HPSEFGF2GBA1MAPK1 | |
| SCHEMBL16261556 | 1.00 | AKT1 (0.56) | AKT1HPSEFGF2GBA1MAPK1 | |
| SCHEMBL13857782 | 1.00 | AKT1 (0.56) | AKT1HPSEFGF2GBA1MAPK1 | |
| SCHEMBL6949878 | 1.00 | AKT1 (0.56) | AKT1HPSEFGF2GBA1MAPK1 | |
| SCHEMBL21628177 | 1.00 | AKT1 (0.56) | AKT1HPSEFGF2GBA1MAPK1 | |
| SCHEMBL13857773 | 1.00 | AKT1 (0.56) | AKT1HPSEFGF2GBA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2026-02-17 | — | — | US | claimed |
| US-20240424062-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2024-12-26 | — | — | US | claimed |
| EP-4397374-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | Mederis Diabetes, LLC (US) | 2024-07-10 | — | — | EP | claimed |
| EP-4286400-A2 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2023-12-06 | — | — | EP | claimed |
| US-20220362345-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2022-11-17 | — | — | US | claimed |
| US-20220348611-A1 | PEPTIDE PHARMACEUTICALS | HERCULES CAPITAL, INC., AS AGENT | 2022-11-03 | — | — | US | claimed |
| EP-4047023-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2022-08-24 | — | — | EP | claimed |
| EP-3444281-B1 | IMPROVED PEPTIDE PHARMACEUTICALS | EUMEDERIS PHARMACEUTICALS INC (US) | 2021-11-03 | — | — | EP | claimed |
| US-11065304-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2021-07-20 | — | — | US | claimed |
| US-20210077629-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | MEDERIS DIABETES LLC (US) | 2021-03-18 | — | — | US | claimed |
| US-20150307550-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | HERCULES CAPITAL, INC., AS AGENT | 2015-10-29 | — | — | US | claimed |
| US-20150290334-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | HERCULES CAPITAL, INC., AS AGENT | 2015-10-15 | — | — | US | claimed |
| EP-2922877-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2015-09-30 | — | — | EP | claimed |
| CN-104918961-A | Improved peptide drugs for insulin resistance | MEDERIS DIABETES LLC | 2015-09-16 | — | — | CN | claimed |
| US-20150031630-A1 | Peptide Pharmaceuticals | HERCULES CAPITAL, INC., AS AGENT | 2015-01-29 | — | — | US | claimed |
| US-20140349928-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES, LLC (US) | 2014-11-27 | — | — | US | claimed |
| WO-2014081864-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | EUMEDERIS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | claimed |
| CN-103796666-A | Improved Peptide Drugs | EUMEDERIS PHARMACEUTICALS INC | 2014-05-14 | — | — | CN | claimed |
| EP-2709645-A2 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2014-03-26 | — | — | EP | claimed |
| WO-2012158962-A2 | IMPROVED PEPTIDE PHARMACEUTICALS | EUMEDERIS PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348611-A1 | PEPTIDE PHARMACEUTICALS | PTMS, DNPEP, ANPEP | AKT1 4244/4885HPSE 269/4885FGF2 871/4885 |
| US-20150031630-A1 | Peptide Pharmaceuticals | PTMS, DNPEP, ANPEP | AKT1 4244/4885HPSE 269/4885FGF2 871/4885 |
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, INSR | AKT1 3260/4885HPSE 3405/4885FGF2 2076/4885 |
| US-20240424062-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | AKT1 2531/4885HPSE 858/4885FGF2 585/4885 |
| US-11065304-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, PTMS | AKT1 2531/4885HPSE 858/4885FGF2 585/4885 |
| US-20150290334-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | AKT1 2531/4885HPSE 858/4885FGF2 585/4885 |
| US-20150307550-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | PTMS, DNPEP, ANPEP | AKT1 4538/4885HPSE 218/4885FGF2 965/4885 |
| US-20140349928-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | AKT1 2531/4885HPSE 858/4885FGF2 585/4885 |
| US-20220362345-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | AKT1 2531/4885HPSE 858/4885FGF2 585/4885 |
| US-20210077629-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | PTMS, DNPEP, ANPEP | AKT1 4538/4885HPSE 218/4885FGF2 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.